Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to -$5.2 million.

  • Abeona Therapeutics' Net Income towards Common Stockholders rose 8294.96% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.2 million, marking a year-over-year increase of 19491.93%. This contributed to the annual value of -$63.7 million for FY2024, which is 1752.77% down from last year.
  • Abeona Therapeutics' Net Income towards Common Stockholders amounted to -$5.2 million in Q3 2025, which was up 8294.96% from $113.7 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Net Income towards Common Stockholders high stood at $113.7 million for Q2 2025, and its period low was -$46.7 million during Q4 2021.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$12.0 million (2025), whereas its average is -$8.9 million.
  • In the last 5 years, Abeona Therapeutics' Net Income towards Common Stockholders tumbled by 24725.27% in 2024 and then surged by 94523.35% in 2025.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Net Income towards Common Stockholders stood at -$46.7 million in 2021, then soared by 84.79% to -$7.1 million in 2022, then crashed by 133.8% to -$16.6 million in 2023, then surged by 44.22% to -$9.3 million in 2024, then surged by 44.26% to -$5.2 million in 2025.
  • Its last three reported values are -$5.2 million in Q3 2025, $113.7 million for Q2 2025, and -$12.0 million during Q1 2025.